Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. / Lauss, Martin; Donia, Marco; Harbst, Katja; Andersen, Rikke; Mitra, Shamik; Rosengren, Frida; Salim, Maryem; Vallon-Christersson, Johan; Törngren, Therese; Kvist, Anders; Ringnér, Markus; Svane, Inge Marie; Jönsson, Göran.
In: Nature Communications, Vol. 8, 1738, 2017.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
AU - Lauss, Martin
AU - Donia, Marco
AU - Harbst, Katja
AU - Andersen, Rikke
AU - Mitra, Shamik
AU - Rosengren, Frida
AU - Salim, Maryem
AU - Vallon-Christersson, Johan
AU - Törngren, Therese
AU - Kvist, Anders
AU - Ringnér, Markus
AU - Svane, Inge Marie
AU - Jönsson, Göran
PY - 2017
Y1 - 2017
N2 - Adoptive T-cell therapy (ACT) is a highly intensive immunotherapy regime that has yielded remarkable response rates and many durable responses in clinical trials in melanoma; however, 50-60% of the patients have no clinical benefit. Here, we searched for predictive biomarkers to ACT in melanoma. Whole exome-and transcriptome sequencing and neoantigen prediction were applied to pre-treatment samples from 27 patients recruited to a clinical phase I/II trial of ACT in stage IV melanoma. All patients had previously progressed on other immunotherapies. We report that clinical benefit is associated with significantly higher predicted neoantigen load. High mutation and predicted neoantigen load are significantly associated with improved progression-free and overall survival. Further, clinical benefit is associated with the expression of immune activation signatures including a high MHC-I antigen processing and presentation score. These results improve our understanding of mechanisms behind clinical benefit of ACT in melanoma.
AB - Adoptive T-cell therapy (ACT) is a highly intensive immunotherapy regime that has yielded remarkable response rates and many durable responses in clinical trials in melanoma; however, 50-60% of the patients have no clinical benefit. Here, we searched for predictive biomarkers to ACT in melanoma. Whole exome-and transcriptome sequencing and neoantigen prediction were applied to pre-treatment samples from 27 patients recruited to a clinical phase I/II trial of ACT in stage IV melanoma. All patients had previously progressed on other immunotherapies. We report that clinical benefit is associated with significantly higher predicted neoantigen load. High mutation and predicted neoantigen load are significantly associated with improved progression-free and overall survival. Further, clinical benefit is associated with the expression of immune activation signatures including a high MHC-I antigen processing and presentation score. These results improve our understanding of mechanisms behind clinical benefit of ACT in melanoma.
U2 - 10.1038/s41467-017-01460-0
DO - 10.1038/s41467-017-01460-0
M3 - Journal article
C2 - 29170503
AN - SCOPUS:85035025088
VL - 8
JO - Nature Communications
JF - Nature Communications
SN - 2041-1723
M1 - 1738
ER -
ID: 188710176